Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Brown Dennis M

2. Date of Event Requiring Statement (Month/Day/Year)
01/25/2013

3. Issuer Name and Ticker or Trading Symbol
DelMar Pharmaceuticals, Inc. [DMPI]

(Last)

(First)

(Middle)

SUITE 720-999 WEST BROADWAY

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	__X__ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Scientific Officer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

VANCOUVER, A2 V5Z 1K5

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,903,542 ⁽¹⁾	I	See Footnote ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrants	02/01/2012	02/01/2017	Common Stock	500,000	$ 0.5 ⁽²⁾	I	See Footnote ⁽³⁾
Warrants	10/03/2011	01/25/2014	Common Stock	100,000	$ ⁽⁴⁾	D
Warrants	02/27/2012	01/25/2014	Common Stock	240,000	$ ⁽⁵⁾	D
Options	02/01/2012	02/01/2022	Common stock	150,000	$ 0.5 ⁽²⁾	D

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Brown Dennis M SUITE 720-999 WEST BROADWAY VANCOUVER, A2 V5Z 1K5	X	X	Chief Scientific Officer

Signatures

/s/ Dennis Brown		02/15/2013
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes 1,253,542 shares of the Issuer's common stock owned directly by Reporting Person and 1,650,000 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares
(2)	Actual exercise price is CAD$0.50 (Canadian dollar). The price listed in this Form 3 is the American dollar equivalent as of February 11, 2013, at which time CAD$0.50 exchanged into USD$0.50.
(3)	Owned by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares
(4)	Through July 25, 2013 the exercise price of such remaining warrants is USD$0.96. Thereafter through the expiration date the exercise price of such remaining warrants shall be USD $1.20.
(5)	Through July 25, 2013 the exercise price of such remaining warrants is USD$0.96. Thereafter through the expiration date the exercise price of such remaining warrants shall be USD $1.20.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.